AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Go Back to All Clinical Trials

AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Brief description of study

If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to previous treatment(s), or for which previous treatment(s) was stopped because the side effects were not tolerable, you may qualify for this Phase I IB study. The main goal of this study is to test the safety of the investigational drug BTCT4465A at different dose levels and schedules to find out what effects, BTCT4465A (given alone or in combination with atezolizumab) has on your cancer.

Clinical Study Identifier: s17-00830

ClinicalTrials.gov Identifier: NCT02500407

Perlmutter Cancer Center

Clinical Trials & Research Studies

AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Brief description of study

Recruitment Status